Mural Oncology plc (NASDAQ:MURA – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 392,800 shares, a decline of 15.7% from the September 30th total of 465,800 shares. Approximately 2.5% of the shares of the stock are sold short. Based on an average daily volume of 94,200 shares, the days-to-cover ratio is currently 4.2 days.
Mural Oncology Price Performance
Shares of MURA traded up $0.08 during mid-day trading on Monday, reaching $3.59. 2,095 shares of the company’s stock traded hands, compared to its average volume of 186,205. The stock has a market cap of $60.76 million and a P/E ratio of -0.34. The stock’s 50-day moving average is $3.32 and its two-hundred day moving average is $3.41. Mural Oncology has a 12 month low of $2.88 and a 12 month high of $17.00.
Mural Oncology (NASDAQ:MURA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. Research analysts predict that Mural Oncology will post -7.59 earnings per share for the current year.
Institutional Trading of Mural Oncology
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. Raymond James assumed coverage on Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock. HC Wainwright started coverage on Mural Oncology in a research note on Thursday, October 17th. They set a “buy” rating and a $18.00 price objective on the stock.
Get Our Latest Stock Analysis on MURA
About Mural Oncology
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Further Reading
- Five stocks we like better than Mural Oncology
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Oil Stocks to Watch Before Earnings Come Out
- What Are Growth Stocks and Investing in Them
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
- Best Stocks Under $10.00
- Alphabet’s Earnings Could Surprise—Should You Buy Now?
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.